NDASUBCUTANEOUSSOLUTION
Approved
Nov 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
FORTEO (teriparatide) by Eli Lilly and Company. Approved for parathyroid hormone analog [epc]. First approved in 2002.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FORTEO (teriparatide) is a recombinant parathyroid hormone analog administered via subcutaneous injection for the treatment of osteoporosis. It works by stimulating osteoblast activity to increase bone formation and bone mass. The drug is indicated for patients at high risk of fracture who require anabolic bone therapy.
$0.425BPart D
LOE ApproachingProduct is nearing loss of exclusivity with moderate competitive pressure (30/100), signaling contraction in brand team size and shift toward defensive commercial strategies.
Mechanism of Action
Pharmacologic Class:
Parathyroid Hormone Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
Started May 2026
36 enrolled
HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
Started Apr 2026
12 enrolled
Hypoparathyroidism
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
Started Mar 2026
10 enrolled
Hypoparathyroidism
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Started Feb 2026
50 enrolled
Hypoparathyroidism
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
Started May 2023
45 enrolled
HypoparathyroidismOsteoporosisFractures, Bone+1 more
Worked on FORTEO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.